Northwest Biotherapeutics Inc has received notification from the National Institutes of Health (NIH) that the Company will receive a National Cancer Institute (NCI) grant providing $645,000 of cancer research support the next two years.

Dr. Alton Boynton, a Northwest Biotherapeutics' founder and its Chief Operating and Scientific Officer, is the Principal Investigator for the research being funded by the grant. "We are very pleased with the receipt of this grant," said Dr. Boynton. "It will provide us with the funding necessary to continue our important study of the significance of one specific protein's function in many different cancers. When a small fragment of this protein is added back to tumor cells, tumor growth is inhibited. This grant will allow us to take the next step in determining the feasibility of using a small polypeptide of this protein as a therapeutic agent for targeting multiple cancers."

Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer.